PREMATURE OVARIAN INSUFFICIENCY DUE COVID-19: WHAT MECHANISM PLAYS A ROLE?

Bakoeva Nilufar Matyokub kizi; Khaydarova Feruza Alimovna

doi:10.5281/zenodo.7775357

PREMATURE OVARIAN INSUFFICIENCY DUE COVID-19: WHAT MECHANISM PLAYS A ROLE?

27.03.2023 International Scientific Journal "Science and Innovation". Series D. Volume 2 Issue 3

Bakoeva Nilufar Matyokub kizi, Khaydarova Feruza Alimovna

Abstract. Today, premature ovarian failure (POF) is one of the most difficult problems of women's health. Relevance. As the main cause of infertility, a decrease in the quality of life of women with POI is a problem that needs special attention. After a confirmed diagnosis, there are currently no methods to restore ovarian function and fertility. The spread of the COVID-19 virus and pandemic-related quarantine measures have led to women's mental health and menstrual irregularities, up to and including amenorrhea. Therefore, it is important to identify risk factors for the development of POI at an earlier stage. Purpose. To evaluate the plasma concentration of KISS1 and BDNF in patients with POI that developed after coronavirus infection. Conclusion. We can say that kisspeptin and BDNF play an important role not only in women's reproductive health, but also in their mental state. Stress due to the coronavirus pandemic, reducing the level of KISS1 and BDNF in the blood can lead to the development of premature ovarian failure. This observation brings important potential insight into the pathogenesis of POI.

Keywords: premature ovarian insufficiency, COVID-19, stress, anxiety, depression, KISS1, BDNF.

References:

1. Abu Helwa HA, Mitaeb AA, Al-Hamshri S, Sweileh WM. Prevalence of dysmenorrhea and predictors of its pain intensity among Palestinian female university students. BMC Womens Health (2018) 18(1):18. doi: 10.1186/s12905-018-0516-1 2. Beck-Peccoz P, Persani L. Premature ovarian failure. Orphanet J Rare Dis. 2006;1:9. 3. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol. 1986;67(4):604–6. 4. Ferreira, R.; Oliveira, J.F.; Fernandes, R.; Moraes, J.F.; Bayard, G.P. The role of angiotensin II in the early stages of bovine ovulation. Reproduction 2007, 134, 713–719. 5. Gunning M.N., Troìa L., Janse F.J. et al. Premature ovarian insufficiency. Female Reprod Dysfunct. 2020:287–307. 6. Jungari SB, Chauhan BG. Prevalence and determinants of premature menopause among indian women: issues and challenges ahead. Health Soc Work. 2017;42(2):79–86. 7. Luborsky JL, Meyer P, Sowers MF, et al. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod 2003; 18: 199-206. 8. Management of women with premature ovarian insufficiency. Guideline of the European Society of Human Reproduction and Embryology [Electronic resource]. – 2015. https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Management-of-premature-ovarian-insufficiency.aspx 9. Meng,W.; Lingwei, M.; Xue, L.; Zhu, Q.; Zhou, S.; Dai, J.; Yan,W.; Zhang, J.;Wang, S. Co-expression of the SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in human ovaries: Identification of cell types and trends with age. Genomics 2021, 113, 3449–3460. 10. Podfigurna-Stopa, A. Premature ovarian insufficiency: the context of long-term effects / A. Podfigurna-Stopa, A. Czyzyk, M. Grymowicz [et al.] // J.Endocrinol. Invest. – 2016. – Vol. 39, №9. – P. 983-990 11. Progetto Menopausa Italia Study G. Premature ovarian failure: frequency and risk factors among women attending a network of menopause clin ics in Italy. BJOG 2003; 110(1):59–63. 12. Shuttleworth, G.; Broughton Pipkin, F.; HunteIn, M.G. In vitro development of pig preantral follicles cultured in a serum-free medium and the effect of angiotensin II. Reproduction 2002, 123, 807–818. 13. Vaz-Silva J, Carneiro MM, Ferreira MC, Pinheiro SVB, Silva DA, Silva AL, Witz CA, Reis AM, Santos RA, Reis FM (2009) The vasoactive peptide angiotensin- (1—7), its receptor Mas and the angiotensin-converting enzyme type 2 are expressed in the human endometrium. Reprod Sci 16:247–256 14. The ESHRE Guideline Group on POI, L. Webber, M. Davies, R. Anderson, J. Bartlett, D. Braat, B. Cartwright, R. Cifkova, S. de Muinck Keizer-Schrama, E. Hogervorst, F. Janse, L. Liao, V. Vlaisavljevic, C. Zillikens, N. Vermeulen, ESHRE Guideline: management of women with premature ovarian insufficiency, Human Reproduction, Volume 31, Issue 5, May 2016, Pages 926–937, https://doi.org/10.1093/humrep/dew027 15. Williams NI, Berga SL, Cameron JL. Synergism between psychosocial and metabolic stressors: impact on reproductive function in cynomolgus monkeys. Am J Physiol Endocrinol Metab (2007) 293(1):E270–6. doi: 10.1152/ajpendo.00108.200 16. Blinov D. V., Khazan P. L., Mnatsakanyan A. N., Korabelnikov D. I., Safarov A. T., Pavlova N. V., Zakharova N. S., Ponomarev D. A., Petrenko D A. Early menopause and premature ovarian failure: problems and prospects. Obstetrics, Gynecology and Reproduction. 2020;14(3):328–345. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2020.173. 17. Galtsev E.V., Kazenashev V.V. Psychosocial discomfort in women with urogenital disorders. Obstetrics, Gynecology and Reproduction. 2007;(2):4–9. 18. Novikova V.A., Fedorovich O.A., Atanesyan E.G. Complex therapy of atrophy of the urogenital tract in premenopausal women with premature ovarian failure. Obstetrics, Gynecology and Reproduction. 2008;(7):14–6. 19. Tabeeva, G.I. Premature ovarian failure - a mystery of the twentieth century / G.I. Tabeeva, N.N. Shamilova, N.A. Zhakhur and others // Obstetrics and Gynecology. - 2013. - No. 12. - S. 16-21. 20. Fakhrutdinova S.S., The role of clinical and genetic markers in predicting premature ovarian failure: author. diss. PhD, Tashkent., 2019. - 97p. 21. Chebotnikova T.V. Premature ovarian failure: the opinion of exports / T.V. Chebotnikova // Bulletin of Reproductive Health. - 2007. - No. 1. - S. 22-32.